The 2nd Annual Meeting of IMMUTOL consortium took place in Budapest between the 27th and 28th of May, 2025 hosted by SRI and organised by INN-Acta.
The first day of the event was focused on progress updates given by several young scientist focused on activities in WP2 (Optimization of monocyte collection to improve advanced VitD3DC generation), WP3 (To develop advanced VitD3DC cells by genetic engineering), and WP4 (Pre-clinical studies for evaluation of the safety and potency of engineered VitD3DC). The presentations were followed by an in-depth, extensive (about three-hour) brainstorming session about the next steps in the R&D activities with the participation of the Advisory Board members.
The second day was dedicated to the overview of activities related to WP7 (Ensure economic viability within and beyond the grant period), WP8 (Communication, dissemination, exploitation, and citizen engagement) and WP1 (Project Management and Coordination).
Additionally, on the second day, there was a two-hour interactive seminar on regulatory guidance for the development of engineered VitD3DC for human therapy, led by representatives of ASP.
Representatives of the EMSP (European Multiple Sclerosis Platform) also attended the meeting as part of the collaboration with the IMMUTOL consortium.
